多替拉韦联合拉米夫定作为HIV-1病毒学抑制患者的维持治疗:ANRS 167 LAMIDOL试验结果
ANRS 167 LAMIDOL是一项开放标签、单臂、多中心试验,评估每日一次多替拉韦(50 mg)联合拉米夫定(300 mg)在病毒学抑制的HIV-1患者中的维持治疗效果。104例患者纳入第二阶段,第48周总成功率为97%(95% CI: 94%-100%),达到设计预期。研究认为该方案是有前景的维持治疗策略。
要点
- 多替拉韦联合拉米夫定维持治疗第48周成功率达97%(95% CI: 94%-100%)。
- 3例治疗失败,未检测到M184V或整合酶耐药突变。
- 该方案在病毒学抑制患者中显示出良好前景。
核心结论
- 多替拉韦联合拉米夫定是HIV-1病毒学抑制患者有前景的维持治疗。
研究设计与样本
- ANRS 167 LAMIDOL为开放标签、单臂、多中心试验,评估每日一次多替拉韦(50 mg)联合拉米夫定(300 mg)在病毒学抑制的HIV-1患者中的疗效。
- 主要入组标准包括血浆病毒载量≤50 copies/mL持续≥2年、CD4最低点>200 cells/mm3且治疗前为野生型HIV。
- 第一阶段(W-8至D0)将当前第三种药物换为多替拉韦;第二阶段(D0至W48)给予多替拉韦联合拉米夫定,共104例患者纳入第二阶段。
主要发现
- 第48周总成功率为97%(95% CI: 94%-100%),达到设计预期。
- 3例治疗失败:1例第4周病毒学失败,1例第32周失访,1例第40周因病毒短暂反弹(pVL 59 copies/mL但对照pVL<50 copies/mL)中断治疗策略。
- 另外2例患者发生3次病毒短暂反弹。
- 失败或病毒短暂反弹后未检测到M184V或整合酶耐药突变。
关键数值与推荐
- 病毒学失败定义为连续两次样本pVL >50 copies/mL。
- 研究设计预期策略有效性≥80%,假设成功率90%,I类错误5%,把握度90%。
- 患者中位年龄45岁,86%男性,72% MSM,87% CDC A期,中位CD4最低点339 cells/mm3,基线CD4 743 cells/mm3,病毒抑制持续时间4.5年。
临床怎么用
- 对于病毒学抑制且符合入组条件的HIV-1患者,可考虑多替拉韦联合拉米夫定作为维持治疗方案。
局限性
- 本研究为开放标签、单臂设计,缺乏对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the dolutegravir+lamivudine combination in virologically suppressed patients living with HIV. METHODS: The ANRS 167 LAMIDOL trial was an open-label, single arm, multicentre trial assessing once-daily dolutegravir (50 mg)+lamivudine (300 mg) in virologically suppressed HIV-1 patients on first-line triple-drug regimens. The main criteria for inclusion in the trial were plasma viral load (pVL) ≤50 copies/mL for ≥2 years, CD4 nadir >200 cells/mm3 and WT HIV prior to treatment initiation. From week -8 (W-8) to day 0 (D0) (Phase 1), the current third agent was switched to dolutegravir. From D0 to W48 (Phase 2), patients received once-daily dolutegravir+lamivudine, except if intolerant or if pVL >50 copies/mL during Phase 1. Virological failure was defined as pVL >50 copies/mL in two consecutive samples. The study was designed to show that the strategy had an efficacy of ≥80%, assuming a 90% success rate with a type I error of 5% and a power of 90%. RESULTS: In total, 104 of 110 patients enrolled in Phase 1 were included in Phase 2. These 104 patients were 86% male, 72% MSM and 87% CDC stage A. Their characteristics were (median): age 45 years, CD4 nadir 339 cells/mm3, baseline CD4 743 cells/mm3 and duration of viral suppression 4.5 years. The overall success rate at W48 was 97% (95% CI: 94%-100%), meeting the design expectation/assumption. Three therapeutic failures occurred: one virological failure at W4, one lost to follow-up at W32 and one interruption of therapeutic strategy at W40 after a blip (pVL 59 copies/mL but control pVL <50 copies/mL). Three viral blips occurred in two additional patients. Neither M184V nor integrase resistance mutations were detected after failure or blips. CONCLUSIONS: Dolutegravir+lamivudine is a promising maintenance therapy in HIV-1-infected patients with controlled virological suppression.
引用
- Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019. PMID: 30476165. doi:10.1093/jac/dky467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。